Efficacy of pegvorhyaluronidase alfa (PEGPH20) plus FOLFIRINOX in a preclinical model of human pancreatic ductal adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e16244
Abstract: e16244Background: Hyaluronan (HA) accumulates in the solid tumor microenvironment, and is associated with poor drug penetration and negative clinical outcomes. Pegvorhyaluronidase alfa (P) is a nov... read more here.
Keywords: pegvorhyaluronidase alfa; folfirinox preclinical; efficacy pegvorhyaluronidase; plus folfirinox ... See more keywords
PCRT16-001: Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic ductal adenocarcinoma (mPDA).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.tps785
Abstract: TPS785Background: PDA is characterized by invasiveness and therapeutic resistance in part due to a desmoplastic stroma and an immunosuppressive microenvironment (Provenzano PP, Hingorani S. Br J Ca... read more here.
Keywords: plus pembrolizumab; study pegph20; pcrt16 001; 001 phase ... See more keywords